Exploring Variability in Infliximab Target Attainment and Implications for Concentration-Guided Dosing (CGD) in Inflammatory Bowel Disease (IBD)

Background: Substantial interindividual variability in infliximab pharmacokinetics and pharmacodynamics (PKPD) complicates dose optimization in patients with inflammatory bowel disease (IBD). Infliximab concentration-guided dosing (CGD) mostly relies on the Therapeutic Window Approach (TWA). Although this approach is widely used in clinical practice, its implications in the setting of substantial variability remain insufficiently characterized. Methods: Model-based simulations evaluated the probability of target (non)-attainment across standard and intensified dosing strategies for intravenous and subcutaneous infliximab. Target attainment was predefined using a therapeutic window (3–7 mg/L) for intravenous infliximab and a threshold (≥12 mg/L) for subcutaneous infliximab. Results: Across dosing strategies, substantial exposure variability resulted in a proportion of patients remaining below the predefined targets. For intravenous infliximab, interval shortening achieved a greater probability of target attainment than dose escalation alone; for example, among patients receiving 5 mg/kg, 50.5% achieved concentrations ≥3 mg/L with Q6W versus 24.5% with Q8W. For subcutaneous infliximab, simulated 180 and 240 mg doses increased the probability of target attainment (≥12 mg/L) versus the approved 120 mg dose, in higher body weight cohorts (72.0% and 86.5%, respectively, vs. 35.5%), potentially highlighting limitations of the current “one-size-fits-all” dosing paradigm. Conclusions: In the presence of substantial infliximab PKPD variability and IBD dynamics, the predefined therapeutic window and fixed threshold may not adequately account for individual variability, potentially contributing to clinical discordance between drug exposure, predefined target attainment, and clinical outcomes. These considerations support evaluating the Target Concentration Approach (TCA) in clinical trials and routine IBD management, given its potential to dynamically adapt dosing to achieve patient-specific target concentration.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-12
DOI
https://doi.org/10.3390/pharmaceutics18111471
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring Variability in Infliximab Target Attainment and Implications for Concentration-Guided Dosing (CGD) in Inflammatory Bowel Disease (IBD)

Zvonimir Petrić
Pharmaceutics
Inflammatory Bowel Disease
article

Exploring Variability in Infliximab Target Attainment and Implications for Concentration-Guided Dosing (CGD) in Inflammatory Bowel Disease (IBD)

Zvonimir Petrić
article en

Abstract

Background: Substantial interindividual variability in infliximab pharmacokinetics and pharmacodynamics (PKPD) complicates dose optimization in patients with inflammatory bowel disease (IBD). Infliximab concentration-guided dosing (CGD) mostly relies on the Therapeutic Window Approach (TWA). Although this approach is widely used in clinical practice, its implications in the setting of substantial variability remain insufficiently characterized. Methods: Model-based simulations evaluated the probability of target (non)-attainment across standard and intensified dosing strategies for intravenous and subcutaneous infliximab. Target attainment was predefined using a therapeutic window (3–7 mg/L) for intravenous infliximab and a threshold (≥12 mg/L) for subcutaneous infliximab. Results: Across dosing strategies, substantial exposure variability resulted in a proportion of patients remaining below the predefined targets. For intravenous infliximab, interval shortening achieved a greater probability of target attainment than dose escalation alone; for example, among patients receiving 5 mg/kg, 50.5% achieved concentrations ≥3 mg/L with Q6W versus 24.5% with Q8W. For subcutaneous infliximab, simulated 180 and 240 mg doses increased the probability of target attainment (≥12 mg/L) versus the approved 120 mg dose, in higher body weight cohorts (72.0% and 86.5%, respectively, vs. 35.5%), potentially highlighting limitations of the current “one-size-fits-all” dosing paradigm. Conclusions: In the presence of substantial infliximab PKPD variability and IBD dynamics, the predefined therapeutic window and fixed threshold may not adequately account for individual variability, potentially contributing to clinical discordance between drug exposure, predefined target attainment, and clinical outcomes. These considerations support evaluating the Target Concentration Approach (TCA) in clinical trials and routine IBD management, given its potential to dynamically adapt dosing to achieve patient-specific target concentration.

PharmaceuticsVol. 18(11)
University of Lisbon (PT)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon